Form 4: GeneDx Holdings Director Jason Ryan Transfers and Sells Shares

GeneDx Holdings director Jason Ryan transferred 141,356 shares to a Grantor Retained Annuity Trust (GRAT) and sold a total of 46,296 shares in multiple transactions.

Summary

• Director Jason Ryan transferred 141,356 shares of GeneDx Holdings Corp. Class A common stock to a Grantor Retained Annuity Trust (GRAT) on November 19, 2024.
• The transfer was for no consideration, and Ryan remains the beneficial owner of the shares held by the GRAT.
• Ryan also sold a total of 46,296 shares of Class A common stock in multiple transactions between November 19 and November 20, 2024.
• The sales were executed at varying prices, ranging from $68.01 to $72.49 per share.
• The weighted average prices for the sales on November 19 ranged from $70.8642 to $72.2565, and on November 20, the weighted average prices ranged from $68.3555 to $70.502.
• The transactions were made through the Jason Ryan Trust u/a dtd 11/25/2018.
• A previous Form 4 filing on October 17, 2024, inadvertently omitted the 141,356 shares held by the Jason Ryan Trust, which have now been transferred to the GRAT.

Sentiment

Score: 5

Explanation: The document is a routine SEC filing detailing insider transactions. It doesn't indicate any positive or negative sentiment about the company's performance, but rather reflects personal financial decisions of a director.

Industry Context

This is a standard SEC Form 4 filing, which is common for corporate insiders who trade company stock. The transactions are not unusual for a director and are likely part of personal financial planning.

Comparison to Industry Standards

• Form 4 filings are a standard part of US stock market regulation, and this filing is consistent with those requirements.
• The transactions are similar to those of other directors and officers who manage their personal portfolios and comply with SEC regulations.
• The use of a GRAT is a common estate planning tool for high-net-worth individuals, including corporate directors.

Stakeholder Impact

• The transactions may have a minor impact on the stock price due to the volume of shares sold, but the overall impact is likely to be minimal.
• The transfer to the GRAT is a personal financial decision and does not directly impact the company's operations or stakeholders.

Key Dates

Keywords

GeneDx Holdings, Jason Ryan, stock sale, share transfer, GRAT, insider trading, Form 4, beneficial ownership